【摘要】 观察重组组织型纤溶酶原激活剂(recombinant tissue-type plasminogen activator, rt-PA)治疗急性心肌梗死的疗效。方法: 53例急性心肌梗死患者,于 60min或 90min内给予rt-PA总量为 50 mg,观察血管再通的临床指标、低血压、出血及寒战等并发症。结果:总血管再通42例(42/53),其中,60 min组及90 min组再通者分别有19例(19/28)、23例(23/25)。不良反应发生中,一过性低血压6例(6/53),轻度出血7例(7/53),发生寒战 1例(1/53),一般不需处理自行消失。结论:rt-PA是一种安全、有效的溶栓剂。更多还原

【Abstract】 To evaluate efficacy and safety of intravenous recombinant tissue-type plasminogen activator (rt-PA) in treatment of acute myocardial infarction (AMI). Methods: Fifty- three patients with AMI admitted to our hospital from April 1995 to December 1997 were confirmed to the inclusion and exclusion criteria of thrombolytic therapy. The patients were divided into two groups, twenty-eight patients in group A and twenty-five patients in group B, and to receive rt-PA intravenous (i. v. ) blous 10 mg in 5 min, follbwed by a 40 mg i. v, infusion over 55 min, or over 85 min. The clinical criteria of reperfusion were evaluated. Results: The reperfusion rate of group A was 67. 9 % (19/28) and group B 92. 0 % (23/25 ). The total reperfusion rate was 79. 3 % (42/53 ) in 53 patients treated with rt-PA. Hypotension, mild bleeding, rigor occurred, respectively, in 11. 3% (6/ 53), 13. 2% (7/53) and 1. 87% (1/53) of patients with rt-PA. Conclusion: rt-PA is a safe and effective thrombolytic agent.更多还原